Vietnam Cryptococcal Retention in Care Study Version 1.0

• Status: Unknown status
• Trial end date: 2018-03-31
• Target enrollment: 0
• Participant gender: All

Summary

It is hypothesized that implementing plasma CrAg screening in clinics providing routine HIV care will enable identification of Vietnamese adult patients with advanced HIV (CD4 ≤100 cells/μL) who have early cryptococcal disease, enable prompt preemptive treatment with high-dose fluconazole, and improve survival.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Hospital for Tropical Diseases, Hanoi, Vietnam
• Collaborator: Centers for Disease Control and Prevention
• Treatments: Fluconazole

Criteria

Inclusion Criteria:

• Aged ≥ 18 years

• Confirmed HIV infection using National Testing Algorithm

• CD4 ≤100 cells/μL

• Able to provide written informed consent

Exclusion Criteria:

• History of prior CM

• Receipt of systemic antifungal medication for more than 4 consecutive weeks within the past 6 months

• Currently taking ART or history of ART for more than 4 weeks within the past year

• Known to be currently pregnant or planning to become pregnant during the study period